CanBas Co

CanBas Co Neto dug

Vrijednost Neto dug od CanBas Co (4575.T) na dan 26. окт 2026. je -1,62 Млрд JPY. Prethodne godine, Neto dug je bio -370,43 М JPY — promjena od 336,73% (niži).

Neto dug

-1,62 МлрдJPY

YoY

336,73%

Zadnja ažuriranja:

Neto dug od CanBas Co je 2023 -1,62 Млрд JPY. Neto dug od CanBas Co je bio 2022 -370,43 М JPY. Pad je time 336,73% niži u odnosu na prethodnu godinu.

Istorija CanBas Co Neto dug

  • 3 године

  • 10 година

  • 25 godina

  • Максимално

Neto dug
Datum
Neto dug
1. јан 2016.
-815,11 М JPY
1. јан 2017.
-889,37 М JPY
1. јан 2018.
-466,28 М JPY
1. јан 2019.
-763,67 М JPY
1. јан 2020.
-362,34 М JPY
1. јан 2021.
-404,76 М JPY
1. јан 2022.
-370,43 М JPY
1. јан 2023.
-1,62 Млрд JPY
Istorija CanBas Co Neto dug
ГОДИНАNeto dugYoY
-1,62 МлрдJPY+336,73%
-370,43 МJPY-8,48%
-404,76 МJPY+11,71%
-362,34 МJPY-52,55%
-763,67 МJPY+63,78%
-466,28 МJPY-47,57%
-889,37 МJPY+9,11%
-815,11 МJPY+184,30%
-286,71 МJPY—

Pristupite ovim podacima preko Eulerpool API-ja

100.000 zahteva/mes. besplatno · bez kartice

CanBas Co Анализа акција

Šta radi CanBas Co? CanBas Co., Ltd. generates revenue through pharmaceutical research and development, focusing on basic anticancer drug discovery and early clinical development. The company develops drug discovery concepts, selects candidate compounds, conducts simple animal studies, and analyzes basic data on anticancer drug candidates entering development. It also performs preclinical studies for clinical trial applications and manages the initial phase of clinical trials. The primary buyers of these services are pharmaceutical companies seeking to advance their anticancer drug pipelines through early-stage research and development. CanBas Co., Ltd. operates with a team of 12 full-time employees, specializing in anticancer drug research. The company's services are tailored for pharmaceutical firms requiring expertise in early-stage drug development, particularly in the discovery and preclinical phases. Its focus on basic anticancer drug research and early clinical development positions it as a specialized provider in the pharmaceutical R&D sector. The firm's business model relies on providing comprehensive research services to pharmaceutical companies, including concept development, compound selection, animal studies, and data analysis. These services are critical for pharmaceutical firms to progress anticancer drug candidates from discovery to early clinical stages, ensuring efficient and effective development pathways for new treatments. CanBas Co je jedna od najpopularnijih kompanija na Eulerpool.

Često postavljena pitanja o akciji CanBas Co

Neto dug kompanije CanBas Co iznosi -1,62 Млрд JPY u 2023. godini.

Neto dug od CanBas Co se promijenio sa -370,43 М JPY na -1,62 Млрд JPY, što predstavlja promjenu od 336,73%. Vrijednost je niži nego prethodne godine.

Na Eulerpool-u možete pronaći potpuni historijski razvoj Neto dug CanBas Co od 2006. — sa godišnjim vrijednostima, grafikonima i detaljnom analizom.

Neto dug je ukupan dug minus gotovina i ekvivalenti gotovine. Pokazuje stvarno dužničko opterećenje nakon računanja dostupnih likvidnih sredstava.

Neto dug's JPY je ključan faktor za investitore. Promene u ovoj metrici mogu signalizirati poboljšane ili pogoršane fundamentalne faktore, direktno utiču na cenu akcije. Na Eulopoolu, možete pratiti Neto dug's CanBas Co istorijski i u realnom vremenu.

Pristupite ovim podacima preko Eulerpool API-ja

100.000 zahteva/mes. besplatno · bez kartice

Билансни лист — CanBas Co

Sve ključne metrike — CanBas Co

Раст